Backus LI, et al. - In 15,059 hepatitis C virus–infected patients with advanced liver disease, researchers assessed the impact of direct-acting antiviral–induced sustained virologic response (SVR) on all-cause mortality and on incident hepatocellular carcinoma (HCC). They defined advanced liver disease by a FIB-4 >3.25. Patients who achieved SVR after direct-acting antiviral treatment exhibited significantly lower all-cause mortality and lower incident HCC rates than those who did not achieve SVR. A history of decompensated liver disease and decreased albumin were identified to have an independent association with increased risk of death.